← Back to Search

Serine Protease Inhibitor

Camostat Mesilate for Paediatric Inflammatory Multisystem Syndrome (RECOVER Trial)

Phase 2
Recruiting
Led By Alan H Bryce, M.D.
Research Sponsored by Alan Bryce
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 and 56 days

Summary

To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.

Eligible Conditions
  • Paediatric Inflammatory Multisystem Syndrome
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 and 56 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 and 56 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in the proportion of patients alive and free from respiratory failure
Secondary study objectives
Adverse Events
Change in the proportion of patients alive and free of ventilator use or ECMO
Clinical Change
+1 more

Side effects data

From 2021 Phase 2 trial • 70 Patients • NCT04353284
9%
Pruritus
3%
Shortness of Breath
3%
Respiratory Infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Camostat Mesylate
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Camostat + Standard of CareExperimental Treatment1 Intervention
Patient will receive SOC tablets and Camostat mesilate 200 mg four times a day after each meal with Standard of Care treatment.
Group II: Placebo + Standard of CarePlacebo Group1 Intervention
Standard of Care will be defined by the investigators in collaboration with the sponsor on the basis of the best available evidence at the time of study initiation with placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Camostat
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Alan BryceLead Sponsor
Alan H Bryce, M.D.Principal InvestigatorAcademic and Community Cancer Research United
~50 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top